Balentine LLC’s Exact Sciences EXAS Stock Holding History

Balentine LLC’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-24	Closed	-$2K	–	389
2020 Q2	$2K	Buy	+24	New	+$1.92K	﹤0.01%	835
2020 Q1	–	Sell	-115	Closed	-$11K	–	673
2019 Q4	$11K	Buy	+115	New	+$10.1K	﹤0.01%	338

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Balentine LLC's EXAS Position: Q3 2020 in Review

Balentine LLC sold out of Exact Sciences (EXAS) in Q3 2020, closing a stake of 24 shares — an estimated $2K sold.

Balentine LLC first reported a position in EXAS in Q4 2019 and held it in 2 quarters. The position peaked at $11K in Q4 2019. 517 funds tracked by Wall St. Rank hold EXAS as of Q3 2020.

Balentine LLC reported no remaining Exact Sciences position as of Q3 2020 after selling out during the quarter.
Balentine LLC sold 24 Exact Sciences shares in Q3 2020, an estimated $2K.
Balentine LLC first reported a position in Exact Sciences in Q4 2019 and held it in 2 quarters.
Balentine LLC's Exact Sciences position peaked at $11K in Q4 2019.
517 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2020.

Based on Balentine LLC's 13F filing for Q3 2020, filed 2 Nov 2020.